Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2/3 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Myasthenia Gravis 4Recurrence 2Optic Neuritis 2Neuromyelitis Optica 2Myelitis, Transverse 2Demyelinating Diseases 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

eculizumab 2ravulizumab 1Plasma Exchange 1Immunoglobulins, Intravenous 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Neuromyelitis Optica × eculizumab × Clear all
NCT02003144 2022-08-23

An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients

Alexion Pharmaceuticals, Inc.

Phase 3 Completed
119 enrolled 17 charts

Demyelinating Diseases, Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis, Recurrence

NCT01892345 2019-06-26

A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)

Alexion Pharmaceuticals, Inc.

Phase 3 Terminated
143 enrolled 18 charts

Demyelinating Diseases, Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡